Takeda holder plans sale of 20,363 ADSs

Takeda Pharmaceutical Company Limited shareholder Elaine Shannon filed a notice of proposed sale of Takeda American Depositary Shares (ADSs).

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited shareholder Elaine Shannon filed a notice of proposed sale of Takeda American Depositary Shares (ADSs). The filing lists up to 20,363 ADSs to be sold through Interactive Brokers LLC, with an aggregate market value of $355,334.35, and an anticipated sale date of August 11, 2026 on the NYSE. The ADSs derive from Restricted Stock Unit Awards – Vested granted as compensation in 2023 and 2024, and the filing notes a prior sale of 4,319 ADSs for $72,351.26 on July 13, 2026.

Key Figures

Proposed ADSs to be sold: 20,363 ADSs Aggregate market value of proposed sale: $355,334.35 Anticipated sale date: 08/11/2026 +4 more

7 metrics

Proposed ADSs to be sold 20,363 ADSs ADSs proposed for sale through Interactive Brokers LLC

Aggregate market value of proposed sale $355,334.35 Value of 20,363 ADSs proposed for sale

Anticipated sale date 08/11/2026 Approximate date for sale of ADSs on NYSE

ADSs sold in past 3 months 4,319 ADSs ADSs sold on 07/13/2026

Proceeds from prior sale $72,351.26 Total proceeds from 4,319 ADSs sold on 07/13/2026

2023 RSU vesting 13,840 ADSs Restricted Stock Unit Awards – Vested on 07/28/2023

2024 RSU vesting 14,938 ADSs Restricted Stock Unit Awards – Vested on 07/30/2024

Key Terms

American Depositary Shares (ADSs), Restricted Stock Unit Awards - Vested, Compensation

3 terms

American Depositary Shares (ADSs) financial

"Securities Information American Depositary Shares (ADSs)"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards - Vested financial

"ADSs | 07/28/2023 | Restricted Stock Unit Awards - Vested"

Compensation financial

"07/30/2024 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Takeda (TAK) shareholder Elaine Shannon report in this Form 144?

Elaine Shannon reports a proposed sale of 20,363 Takeda ADSs with an aggregate market value of $355,334.35, expected to be sold through Interactive Brokers LLC on or after August 11, 2026.

How many Takeda (TAK) ADSs are proposed for sale and what is their value?

The filing lists a proposed sale of 20,363 ADSs with an aggregate market value of $355,334.35. These American Depositary Shares are expected to be sold on the NYSE through Interactive Brokers LLC.

What prior Takeda (TAK) share sales does Elaine Shannon disclose?

The filing discloses that on July 13, 2026, Elaine Shannon sold 4,319 ADSs for total proceeds of $72,351.26. This transaction is reported under the section covering securities sold during the past three months.

What is the source of the Takeda (TAK) ADSs being sold under this Form 144?

The ADSs relate to Restricted Stock Unit Awards – Vested granted as compensation by Takeda. Awards include 13,840 ADSs vested on July 28, 2023 and 14,938 ADSs vested on July 30, 2024.

Which broker and market are involved in the proposed Takeda (TAK) ADS sale?

The proposed sale of 20,363 ADSs is to be executed through Interactive Brokers LLC located in Greenwich, Connecticut, with trading expected on the NYSE beginning around August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:31 PM Accepted by SEC EDGAR 08/10/2026 - 04:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002009368
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number	001-38757
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Elaine Shannon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	President, Global Supply & Quality

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich, CT 06830	20363	355334.35	158131870	08/11/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/28/2023	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			13840	07/28/2023	Compensation
ADSs	07/30/2024	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			14938	07/30/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elaine Shannon 45-55 HAYDEN AVENUE LEXINGTON, MA 02421	ADSs	07/13/2026	4319	72351.26

144: Remarks and Signature

Remarks	Sale during the past 3 months was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026. Date of such sale reflects the date on which the administrative agent initiated this process, and such sales may not have settled as of the date hereof.
Date of Notice	08/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Samuel Ntonme, by power of attorney for Elaine Shannon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)